As BIOSPAIN 2026 comes to end, delve into what as been at the center of this edition's discussion: what comes after we have ...

PMOS, formerly PCOS, still has no approved dedicated drug. Discover the new PMOS treatments in development, from GLP-1s to ...

Brain biomarkers were long hard to pin down. See how new Parkinson's and Alzheimer's biomarkers are changing that.

Learn how to choose and integrate automated liquid handling solutions while overcoming challenges and supporting flexible lab ...

Discover biotech and big pharma’s emerging interest in developing macrocyclic drugs for cardiometabolic diseases.